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Effects of Intestinal Microbiota on 
Brain Development in Humanized 
Gnotobiotic Mice
Jing Lu1, Lei Lu1, Yueyue Yu1, Joanne Cluette-Brown2, Camilia R. Martin3 & Erika C. Claud1
Poor growth in the Neonatal Intensive Care Unit is associated with an increased risk for poor 
neurodevelopmental outcomes for preterm infants, however the mechanism is unclear. The microbiome 
has increasingly been recognized as a modifiable environmental factor to influence host development. 
Here we explore the hypothesis that the microbiome influences both growth phenotype and brain 
development. A germ free mouse transfaunation model was used to examine the effects of preterm 
infant microbiotas known to induce either high growth or low growth phenotypes on postnatal 
brain development. The microbiome which induced the low growth phenotype was associated with 
decreases in the neuronal markers NeuN and neurofilament-L as well as the myelination marker MBP 
when compared to the microbiome associated with the high growth phenotype. Additionally, poor 
growth phenotype-associated microbiota was associated with increased neuroinflammation marked by 
increased Nos1, as well as alteration in IGF-1 pathway including decreased circulating and brain IGF-1, 
decreased circulating IGFBP3, and increased Igfbp3 brain mRNA expression. This study suggests that 
growth-associated microbiota can influence early neuron and oligodendrocyte development and that 
this effect may be mediated by effects on neuroinflammation and circulating IGF-1.
Around the time of birth and thereafter, newborns are rapidly colonized with a community of microbes that starts 
the process of gut microbiota assembly and continues during the first 2–3 years of life1. The early assembly of 
microbiota has been shown to shape host development of the gut2,3, endocrine system4, lung5, liver6,7, bone8 and 
brain1,9,10. More specifically, this window of early gut microbiota development parallels nervous system develop-
ment across prenatal and early postnatal stages. Brain development such as neurogenesis, neuronal migration, 
axonal and dendritic growth, synaptogenesis, and myelination begins early in prenatal life and continues post-
natally10,11. The concurrent, early, postnatal window of both microbiome and brain development is a critical time 
period for investigation to determine whether an interplay between these developmental processes exists.
Preterm infants, particularly those born at less than 32-week of gestational and/or with a birth weight less than 
1500 g, are at risk for adverse neurological outcomes including later cognitive and behavioral deficits12,13. These 
deficits are considered to be the consequence of complications associated with prematurity which impairs brain 
development14. Furthermore, while critical development for full term infants occurs in utero under limited influ-
ence of microbiota, for preterm infants it largely occurs ex utero shaped by environmental influences including 
the development of the microbiome. The microbiome of the preterm infant is shaped by the NICU environment 
including instrumentation, frequent antibiotic use, multiple care givers, and a hospital environment. The com-
bination of postnatal insults and developmental immaturity of both the gut microbiota and the nervous system 
makes preterm infants a unique population in which to study the impact of initial microbiota colonization and 
development on brain development.
Recently, our group demonstrated that germ free (GF) mice colonized with two different human preterm 
infant fecal samples yielded distinct growth phenotypes15. We and others have previously demonstrated that the 
microbiome of preterm infants changes over time with distinct clustering at less than 2 weeks of life16,17. Thus, to 
study the effects of these early microbial colonization patterns on host development, samples chosen for transfau-
nation were from human preterm infants prior to two weeks of life with different growth rates. Our data showed 
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that a preterm infant growth phenotype could be transferred to mice via the microbiota. Mice colonized with 
microbiota from a preterm infant with good growth (>10 gm/k/day weight gain, Microbiota PRETERM INFANT-High 
(MPI-H)) had significantly more weight gain (20%) postnatally than mice colonized with microbes from a pre-
term infant with poor postnatal growth (<10 gm/k/day weight gain, Microbiota PRETERM INFANT-Low (MPI-L)). We 
demonstrated that MPI-L mice had increased intestinal inflammation using nuclear factor-kappa beta (NF-κB) 
activation as a marker and by investigating production of NF-κB-mediated inflammatory cytokines at both the 
intestinal and serum level when compared to MPI-H mice. These differences were seen at baseline, even without 
a secondary insult and demonstrated that the gut microbiota not only has local intestinal effects, but also has sys-
temic effects including inducing a systemic inflammatory response and influencing overall growth.
Poor early postnatal growth after preterm birth is clinically associated with short term morbidities in the 
neonatal intensive care unit as well as long-term adverse neurological outcomes. Although the mechanism is not 
fully understood, contributing independent factors include severity of illness and nutritional delivery18–20. We 
hypothesized that early microbiota development also influences brain development contributing to long term 
neurodevelopmental potential. Specifically, we postulated that microbiota associated with impaired growth phe-
notypes adversely influence brain development. We thus investigated several potential mechanisms including 
growth factors, neuroinflammation, brain fatty acid compositions, and microbial metabolites by which microbi-
ota may influence both growth and neurodevelopment.
Deficits in growth hormones such as circulating insulin-like growth factor 1(IGF-1) contribute to adverse 
outcomes in preterm infants including poor postnatal growth21–24. Patients with mutations in the igf-1 gene or in 
the igf1r gene have severe somatic growth failure, microcephaly, and severe cognitive impairment25. Specifically 
in preterm infants, IGF-1 circulating levels are positively correlated with birth weight, length, and head circum-
ference26. Furthermore, circulating IGF-1 has specifically been shown to be an important regulator of brain cell 
proliferation, apoptosis, myelination, neurogenesis, maturation and differentiation27. Studies in GF mice have 
reported that microbiota-regulated IGF-1 levels in mice drive juvenile growth28. Since IGF-1 regulates brain 
development and microbiota-mediated IGF-1 has been shown to regulate growth, we hypothesized that the two 
growth phenotype associated-microbiomes could regulate both somatic growth and brain development through 
IGF-1.
Preterm infants are at high risk for neuroinflammation resulting from exposure to maternal, fetal, and 
neonatal infection and non-infectious insults29. Neuroinflammation can give rise to common neonatal 
brain injuries such as periventricular leukomalacia (PVL) and hypoxic-ischemic encephalopathy30. These 
neuroinflammation-related brain injuries are associated with neurological disorders such cerebral palsy, autism 
and schizophrenia31,32 and can contribute to long term adverse neurological outcomes such as motor and cogni-
tive deficits33,34. Gut microbial cell wall components continually interact with the innate immune system to induce 
the secretion of cytokines. In our previous study15, pro-inflammatory mediators such as IL-1β, TNF, and IFNγ 
were elevated in the serum of mice colonized with microbes from the poor growth infant, reflecting a systemic 
effect by the microbiome. However, the effect of the microbiota on neuroinflammation such as IL-1β and TNF 
was not investigated at the time.
Long-chain polyunsaturated fatty acids (PUFA) such as arachidonic acid (AA) and docosahexaenoic acid 
(DHA) are essential structural and functional constituents of cell membranes and are required for the growth and 
function of the brain and vascular systems35. Brain accumulation of monounsaturated fatty acids such as oleic 
acid (C18:1) and tetracosenoic acid (24:1), which is elongated from C18:1 ω-9, is very high during the early post-
natal period when myelin is being formed most rapidly36. The incorporation of these fatty acids in the fetal brain 
occurs mainly during the last trimester of pregnancy and continues to the end of two years of life37,38 thus preterm 
infants are at high risk for PUFA deficiency and this deficit-related impaired visual and cognitive functions39–42.
Other trajectories of microbiota-originated communication with the brain might involve their metabolites 
such as short chain fatty acids (SCFAs) generated by enteric bacterial fermentation43. SCFAs have been implicated 
in the pathogenesis of several neurodegenerative diseases44, with perhaps the strongest evidence that SCFAs have 
roles in the gut-brain axis coming from a study demonstrating that SCFA-producing bacteria or butyrate itself can 
decrease the blood-brain barrier (BBB) permeability in GF mice45.
The microbiome has increasingly become a focus of studies of host development and functions46–48. However, 
its impact on early postnatal brain development remains elusive. The cause of poor neurodevelopmental outcome 
in preterm infants is certainly multifactorial; however a key distinctive of the microbiome is that it is modifiable 
for an individual infant in a time frame parallel to brain development. In this study, we introduced two growth 
phenotype-associated microbiotas to pregnant GF mice and investigated the influence of these two distinct 
microbial communities on the postnatal brain development of the offspring. We further investigated multiple 
potential mechanisms by which microbiota can affect brain development and demonstrated that the microbiota’s 
effects may be partially mediated by circulating IGF-1 levels and markers of neuroinflammation.
Results
Microbiota influences neuronal development. One of the hallmarks of brain development is neuronal 
differentiation with permanent exit from the mitotic cycle. NeuN is a 46/48-kD nuclear protein antigen used 
widely to identify postmitotic mature neurons in both research and diagnostics49. Increased expression of neu-
rofilament proteins (NFs), which provide support for axonal growth, is closely associated with continued growth 
of axons and axon diameter50. To examine whether microbial colonization impacts early neuronal development, 
we measured the expression levels of NeuN and NF, markers of early development in the brain. In our study, we 
colonized pregnant GF mice at E15 with the human microbiome of interest, and the newborn pups were not sep-
arated from the colonized mother until weaning thus the offspring acquired a microbiota reflecting the human 
microbiome of interest from contact with the mother15. The fecal samples were from the first two postnatal weeks 
in human preterm infants with two different growth rates (MPI-H and MPI-L) during their NICU course, and 
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resulted in corresponding high and low growth phenotypes in the pup offspring15. In this study, western blot 
analysis of cerebral cortex homogenates with anti-NeuN antibody showed significantly increased levels of NeuN 
expression in MPI-H mice colonized with microbiota from a preterm infant with good growth compared with 
GF pups at two weeks of age (Fig. 1A,B). MPI-L pups colonized with microbiota from a preterm donor with poor 
growth demonstrated significantly lower NeuN expression compared to MPI-H mice colonized with a preterm 
donor with a good growth at four weeks of age (Fig. 1C,D). These observations were further demonstrated by 
immunostaining (Fig. 1E,F) at both two and four weeks of age.
There was no significant difference in NFL expression among the experimental mice at two weeks of age 
(Fig. 1G,H). At four weeks of age, MPI-L mice had significantly lower expression of NFL when compared to MPI-H 
mice (Fig. 1I,J). Taken together, these data demonstrate a microbiota-dependent delay of neuronal development 
in the brains of MPI-L mice compared to MPI-H mice.
Microbiota influences oligodendrocyte development. Nerve/glial-antigen 2 (NG2) is expressed 
by oligodendrocyte precursor cells (OPC) but not by any other mature neural cell-type51. OPCs under defined 
regulation first differentiate into premyelinating oligodendrocytes (OLs) where OL-specific transcription fac-
tors such as Olig2 drive the transcription of genes required for differentiation52. Differentiated OLs myelinate 
axons of neurons to ensure rapid propagation of action potentials and provide metabolic support for axons. 
Myelin basic protein (MBP) is the major structural element of myelin and is essential for axon myelination, 
compacting, and wrapping and is developmentally regulated53. Protein expression levels tested by western blot 
demonstrated that cerebral cortex expression of NG2 was not statistically different among the three experi-
mental groups at two weeks of age (Fig. 2A,B). Expression of Olig2 was higher in MPI-H compared to GF mice 
at 2 weeks of age (Fig. 2A,C). NG2 and Olig2 were only minimally detected at four weeks of age in all groups 
(data not shown).
Immunoblot analysis of cerebral cortex samples from two-week old mice revealed that MPI-L demonstrated 
significantly reduced MBP expression when compared to MPI-H mice (Fig. 2D,E). MBP expression at four weeks 
of age was not different among these groups (Fig. 2F,G). These results were further demonstrated by immunos-
taining as shown in Fig. 2H,I. These data demonstrate that microbiota from a poor growth preterm infant is asso-
ciated with delayed oligodendrocyte development and myelination in the early (two weeks of age) postnatal brain.
Microbiota influences neurotransmission pathways. Glutamate and γ-aminobutyric acid (GABA) are 
the main excitatory and inhibitory neurotransmitters in the central nervous system, respectively. Together they 
are involved in over 85% of the synapses that underlie learning and memory, motor activity, sensory and many 
other functions in the mammalian cortex54–56. Serotonergic and dopamine signaling control mood, sleep, concen-
tration, and motivation. Dysfunction and imbalance of these pathways can contribute to cognitive deficits57,58. It 
has been suggested that changes in serotonergic signaling may contribute to the altered anxiety phenotype in GF 
mice59. Since previous molecular and behavioral studies have implicated the gut microbiota in the development 
of neuronal circuits9,60, we studied the expression of synaptic transmission plasticity-related genes by quantita-
tive RT-PCR (Fig. 3). Microbiota indeed impacted Glutamatergic, GABAergic, serotonergic, dopaminergic and 
ion channel pathways. Furthermore MPI-L and MPI-H had differential impacts on different neurotransmission 
pathways. For example, at four weeks of age, MPI-L was generally associated with increased glutamatergic path-
way activity demonstrated by increased expression levels (red) and decreased serotonin and dopamine pathway 
expression levels (blue) in Fig. 3 when compared to MPI-H.
Colonization of GF mice with human fecal samples from a preterm infant with poor growth is 
associated with neuroinflammation in the brain. IL-1β and TNF are major regulators of neuroinflam-
mation associated with an inflammatory/cytotoxic phenotype in the brain61,62. Neuronal nitric oxide synthase 
(NOS1) is a key enzyme implicated in neurotoxicity in the perinatal cortex63,64. As a potential mechanism by 
which different microbiota can affect brain development, we examined the overt inflammatory status in the devel-
oping brain. Our data showed that at two weeks of age, GF mice had significantly higher Il-1β and Tnf mRNA 
expression in the brain when compared to MPI-L and MPI-H mice (Fig. 4A,B). MPI-L mice exhibited significantly 
higher Nos1 expression when compared to GF and MPI-H mice in the cortex (Fig. 4C). These data demonstrate 
that microbiota can affect the neuroinflammation status of the developing brain.
Colonization of GF mice with human fecal samples from preterm infants did not change the 
brain fatty acids profile. Preterm infants are subjected to brain fatty acid deficiency because fatty acid 
accumulation in the brain is at the highest rate from the intrauterine and neonatal period up to two years of age37. 
To evaluate if there were effects of growth phenotype–related preterm infant microbiota on brain fatty acid com-
position, we measured several PUFAs and myelin-related fatty acid levels in the brain. The levels of C20:4 (AA) 
(Fig. 5A), C22:6 (DHA) (Fig. 5B) and C18:1 (Oleic acid) (Fig. 5C) at both two weeks and four weeks of age were 
not different among GF, MPI-L and MPI-H mice, demonstrating the colonization of microbiota from either a poor 
growth preterm infant or a good growth preterm infant did not influence these fatty acids in the brain.
Effects of different microbiota colonization to GF mice on fecal SCFA concentration. SCFAs 
are among the major metabolites produced by anaerobic bacterial fermentation in the gut65. We found that fecal 
contents of acetic acid (Fig. 6A), propionic acid (Fig. 6B), butyric acid (Fig. 6C), isovaleric acid (Fig. 6D), hexa-
noic acid (Fig. 6E), and isobutyric acid (Fig. 6F) were not different among the three groups at four weeks of age, 
demonstrating the colonization of microbiota from either a poor growth preterm infant or a good growth preterm 
infant did not influence the SCFA production in the fecal samples in our experimental setting.
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Figure 1. Regulation of neuronal development by gut microbiota. Neuron development was evaluated by 
western blot and immunohistochemistry. (A, B) Representative images and quantification of western blots of 
the expression of NeuN at two weeks of age in GF, MPI-L and MPI-H mice (all n = 3). (C, D) Representative 
images and quantification of western blots of the expression of NeuN at four weeks of age in GF (n = 5), MPI-L 
(n = 3) and MPI-H mice (n = 4). (E, F) Representative images of immunofluorescence labeling of NeuN (Red) 
specific for neurons, counterstaining with DAPI (blue) to visualize all cells, showing decreased NeuN in mouse 
cortex sections in the MPI-L pups compared to MPI-H mice at both two and four weeks of age. (G, H, I, J) 
Representative images and quantification of western blots showing the expression of NFL at two and four weeks 
of age, respectively (for two weeks n as indicated for previous data; for four weeks GF (n = 7), MPI-L (n = 5) and 
MPI-H mice (n = 4)). One-way ANOVA was used to detect the difference among groups. Bars with indicates 
a significant difference between the two bars (at least p < 0.05). Blots were cropped and the original blots are 
presented in Supplementary Figure S1.
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Figure 2. Regulation of cortex myelination by gut microbiota. Development of oligodendrocytes was evaluated 
by western blot and immunohistochemistry. (A, B, C) Representative images and quantification of western 
blots showing the expression of NG2, an oligodendrocyte progenitor cell marker, and Olig2, a marker for pre-
myelinating oligodendrocytes at two weeks of age in GF, MPI-L and MPI-H mice (all n = 3). Representative 
images and quantification of western blots showing the expression of MBP (D, E) at two weeks of age in GF 
(n = 5), MPI-L (n = 5) and MPI-H mice (n = 5) and (F, G) at four weeks of age in GF (n = 7), MPI-L (n = 5) and 
MPI-H (n = 4) mice. (H, I) Representative images of immunostaining of MBP (green), counterstaining by DAPI 
(blue) for nuclei, showing the decreased MBP in mouse cortex sections in the MPI-L pups compared with MPI-H 
mice at both two and four weeks of age. One-way ANOVA was used to detect the difference among groups. 
Bars with indicates a significant difference between the two bars (at least p < 0.05). Blots were cropped and the 
original blots are presented in Supplementary Figure S2.
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Colonization of germ free mice with human fecal samples from a preterm infant with poor 
growth resulted in decreased circulating IGF-1, IGFBP3 levels and brain IGF-1 levels and 
increased Igfbp3 brain transcript levels. To understand the mechanisms by which different growth phe-
notype related-microbiota colonization resulted in different brain development phenotypes, we tested whether 
the effect of microbiota is mediated through circulating levels of IGF-1. Serum levels of IGF-1 measured by ELISA 
were significantly lower in GF and MPI-L mice compared with the MPI-H mice at two weeks of age (Fig. 7A, 
p < 0.05). At four weeks of age, MPI-L mice still had significantly lower circulating IGF-1 compared to MPI-H mice 
(Fig. 7B, p < 0.05). In serum, the majority of the IGFs exist in a 150-kDa complex including the IGF molecule, IGF 
binding protein 3 (IGFBP-3), and the acid labile subunit (ALS). This complex prolongs the half-life of serum IGFs 
and facilitates their endocrine actions. We found that there was no difference in serum IGFBP3 levels among the 
mice at two weeks of age (Fig. 7C), but at four weeks of age, IGFBP3 serum level in MPI-L mice was significantly 
lower than that of the MPI-H mice (Fig. 7D, p < 0.05). These data suggest that poor growth-phenotype related 
microbiota is associated with reduced circulating IGF-1 and IGFBP3 levels in mouse pups.
To assess contribution of circulating IGF-1 to brain IGF-1 status, we measured local production of IGF-1 in 
the brain at both the protein and mRNA level. The brain IGF-1 levels of GF mice were significantly higher than 
Figure 3. Effect of microbiota on gene expression related to neurotransmission pathways. Expression of 
genes related to neurotransmission pathways. aRepresents ionotropic receptors and brepresents metabotropic 
receptors. Transcript values measured by RT-PCR were first normalized to Gapdh (n = 3–9 for two weeks 
and n = 3–7 for four weeks). Comparison to MPI-H values as fold changes are presented in heatmap format to 
highlight differential effects on gene expression in GF, MPI-L and MPI-H mice. *Indicates a statistical difference 
when compared to MPI-H mice. In this pseudo-colored heat map, increasing red intensities indicate genes with 
higher expression levels compared to MPI-H mice, and increasing blue intensities indicate genes with lower 
expression levels compared to MPI-H mice.
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those of MPI-L and MPI-H pups (at least p < 0.05) at two weeks of age (Fig. 8A). At four weeks old, the levels 
of IGF1 in the brains of both GF and MPI-L mice were significantly lower than those of MPI-H mice (Fig. 8B). 
However, there were no differences in brain Igf1 (Fig. 8C,D) or Igf1r (Fig. 8E,F) mRNA levels among the three 
experimental groups at either two weeks or four weeks old of age.
Figure 4. Effects of microbiota on neuroinflammation. Relative brain transcripts of Il-1β (A), n = 3–9 at two weeks 
and n = 2–8 at four weeks of age), Tnf (B), n = 3–9 at two weeks and n = 2–6 at four weeks of age), and Nos1 (C), 
n = 3–8 at two weeks and n = 2–7 at four weeks of age) were measured by RT-PCR. Two-way ANOVA was used to 
detect the effects of age and microbiota among the groups. Post-hoc test was used to identify differences when a 
main effect was noted. Bars with  indicates a significant difference between the two bars (at least p < 0.05).
Figure 5. Effects of microbiota on brain fatty acid profile. Brain AA (A), DHA (B), and oleic acid (C) contents 
were measured by GC in the brain tissues collected both at two (n = 3–8) and four (n = 3–6) weeks of age. Two-way 
ANOVA was used to detect the effects of age and microbiota among the groups. Data are presented as mol% ± s.e.m.
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IGFBP3 antagonizes the local biologic effects of IGF-1 by having higher affinity for IGF-1 than the IGF-1 
receptor66,67. At two weeks of age, there were no differences in Igfbp3 transcript levels among the three exper-
imental groups (Fig. 8G). At four weeks old of age, MPI-L mice had significantly higher Igfbp3 mRNA levels 
than MPI-H mice (Fig. 8H, p < 0.05). These data demonstrate that poor growth phenotype-associated microbiota 
resulted in decreased circulating and brain IGF-1, decreased circulating IGFBP3 and increased IGFBP3 brain 
levels when compared to good growth phenotype-associated microbiota.
Colonization of GF mice with human fecal samples from a preterm infant with poor growth 
decreased liver IGF-1 levels. Liver synthesis and secretion of IGF-1 is responsible for 80% of the circulat-
ing IGF-1. To test whether the effect of different microbiota on circulating IGF-1 level is due to liver production 
of IGF-1, we examined both the protein and transcript levels of IGF-1 in the liver. IGF-1 tissue levels measured 
from liver homogenates by ELISA were significantly lower in MPI-L mice compared to GF mice (Fig. 9A, p < 0.05) 
at four weeks of age. Liver Igf1 transcript levels were not affected by the different microbiota (Fig. 9B). Our data 
demonstrate that microbiota from a preterm infant with poor growth negatively regulated liver levels of IGF-1.
Discussion
Growth velocities in the lowest quartile of extremely preterm infants while they are in the neonatal intensive care 
unit are associated with an increased risk of long term neurodevelopmental impairment68. Using a humanized 
mouse model of microbiome-induced differential growth phenotypes15, we demonstrate that the intestinal micro-
biota is an important mediator in this growth-neurodevelopment relationship with an impact on IGF-1, brain 
development, and neuroinflammation. Together with our previous study15, our body of work demonstrates that 
early infant intestinal microbiota may influence both growth and brain development phenotypes.
In our study, we colonized pregnant GF mice at E15 with specific growth-phenotype associated microbial 
communities so that pups would be naturally colonized with these distinct microbial communities. GF mice 
colonized with microbiota from a poor growth human infant exhibited decreased NeuN and NFL at four weeks of 
age and reduced MBP expression in the cortex at two weeks of age when compared to mice colonized with micro-
biota from a good growth human infant, suggesting an altered neuronal development and myelination process. 
Microbiota did not change the brain fatty acid composition and fecal SCFA production, but had diverse impact 
on neurotransmission pathways. Furthermore, the mechanisms by which microbiota can alter brain development 
and functions might be due to an impact on circulating level of IGF-1and local inflammation. In our study, micro-
biota from an infant with poor postnatal growth is associated with lower levels of circulating and brain levels of 
IGF-1 and higher levels of neuroinflammation markers.
Our study extends the growing body of research to support the view that normal gut microbiota plays a 
critical role in shaping brain functions9,69–71. Although previous studies have provided a strong foundation for 
establishing the gut-brain axis concept by modulating gut microbiota in adult animals9,72, few studies have 
Figure 6. SCFA analysis of fecal samples. Effects of microbiota on fecal acetic acid, propionic acid, and butyric 
acid at four weeks of age were measured by GC. Fatty acid composition is expressed as a percent of total 
identified fatty acids and concentrations as µg/mg sample. One-way ANOVA was used to detect differences 
among groups.
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demonstrated the connection between gut microbiota and neonatal brain development59. Interestingly, in one 
of the earliest studies demonstrating the gut-brain connection, Sudo et al.59 emphasized that normalization of 
hypothalamic-pituitary-adrenal response to stress in GF mice existed only when GF mice were reconstituted 
with SPF feces at one week old but not at three weeks of age. These observations suggest that early establish-
ment of the microbial community might be critical in shaping the brain function and have long-lasting effects 
on behaviors. Recently, the first study to demonstrate associations between the gut microbiota and cognition in 
human infants has been published73. In the study, Carlson et al. demonstrated that fecal microbial community 
diversity from one year old infants was associated with variation on the Mullen score, visual reception scale, 
and expressive language scale at two years of age. It has been suggested that there is an early parallel window of 
microbiome and brain development10. Microbiome colonization begins around birth and continues to develop 
into a relative stable community during the first 2–3 years of life10. Critical brain development such as increases 
in cortical thickness and surface area mostly by neurogenesis occurs faster during the first year than in the 
second year of life74. Axon diameters and myelin sheaths undergo rapid growth as a reflection of white matter 
maturation during the first two years of life75,76. Our study characterized the effect of the early microbiome, 
from less than two weeks of life in preterm infants, on neuronal and myelination development in the early post-
natal ages (pre-weaned and post weaned time points in mice which corresponds to time points in the first year 
of human life), providing direct evidence that there is a critical window in early life during which microbiota 
can influence brain development.
Other impacts of microbiota on brain development observed in this study includes the complex and diverse 
alterations in gene expression in multiple neurotransmission pathways, including glutamatergic, GABAergic, sero-
tonin and dopamine pathways as well as neurotransmitter transporters and ion channels. Even though the mecha-
nisms by which microbiota affect these pathways are beyond the scope of this study, these findings provide evidence 
that microbiota can have diverse impacts on the brain. For instance, developmental changes in NMDA receptor 
composition at early postnatal ages may influence the balance of plasticity and stability that is critical for information 
processing and storage and precedes the associative learning77. Thus our data also suggests that early microbiota col-
onization associated with a poor growth outcome might pose neurological disadvantages for neonates by affecting 
neurotransmission pathways.
Figure 7. Effects of microbiota on the levels of circulating IGF-1 and IGFBP3. Circulating IGF-1 (A,B) and 
IGFBP3 levels (C,D) were measured by ELISA at both two weeks (n = 3–6) and four weeks (n = 3–8) of age. 
One-way ANOVA was used to detect the difference among the groups. Bars with  indicate a significant 
difference between the two bars (at least p < 0.05).
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Extremely preterm infants exposed to a prolonged systemic inflammatory response are at an increased risk 
for impaired neurodevelopment78,79. A persistent systemic inflammatory response during a sensitive period of 
postnatal life in a hospital setting influences critical phases of myelination and cortical plasticity29,30. Our previous 
study demonstrated a systemic proinflammatory profile in mice colonized with microbiota from a preterm infant 
Figure 8. Effects of microbiota on the brain levels of IGF-1, IGF1R and IGFBP3. Brain IGF-1 (A,B) were 
measured by ELISA at both two weeks (n = 3–7) and four weeks (n = 2–6) of age. Relative brain transcripts of 
Igf1 (C, n = 2–9 for two weeks and D, n = 2–7 for four weeks), Igf1r (E, 2 weeks) and (F, four weeks), and Igfbp3 
(G, two weeks) and (H, 4 weeks) (all n = 3–9 for two weeks and n = 2–8 for four weeks) were measured by RT-
PCR. One-way ANOVA was used to detect the difference among the groups. Bars with  indicates a 
significant difference between the two bars (at least p < 0.05).
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with poor growth15. Elevated proinflammatory cytokines have been associated with brain injuries in the devel-
oping neonatal brain80,81. However, even though phenotypic changes in brain development have been linked to 
systemic changes of proinflammatory cytokines, the underlying mechanisms that transfer systemic inflammation 
to the brain remains elusive29. Possible mechanisms by which peripheral cytokines might influence brain inflam-
mation include the immature development of the BBB82 and interaction between TLR ligands and brain endothe-
lial TLR receptors followed by activation of the downstream signaling to induce inflammation in the brain83. 
Perinatal neuroinflammation has been associated with neurotoxicity63 and dysfunctions of synaptic organization 
in the developing brain29. In animal models of neonatal meningitis, cerebral cortex and hippocampal expression 
of TNF, IL-1β and IL-6 were upregulated after S. Pneumonie or S. agalactiae infection in the neonatal rats84. 
We demonstrate that, even without induced active infection, different baseline microbiota colonization patterns 
result in distinct inflammatory profiles in the brain as evidenced by the elevated expression levels of Nos1 in MPI-L 
mice and Il-1β and Tnf in GF mice. Our data suggest that the effects of microbiota on neuroinflammation can be 
another mechanism by which microbiota affect brain development.
The effect of microbiota on serum IGF-1 levels could also contribute to the altered brain development. IGF-1 
has been shown to play prominent roles in CNS development and maturation85. Homozygous Igf1 −/− mice at 
two months of age had reduced brain weights, white matter size and spinal cord due to the decreased numbers of 
axons and oligodendrocytes. Myelinated axons, the volume of the dentate gyrus granule cell layer, and the num-
ber of striatal parvalbumin-containing cells were also reduced86. Moreover, IGF-1 is very important in prenatal 
and early postnatal neurogenesis87 as increased IGF-1 levels result in increased numbers of total neurons in the 
cerebral cortex. In this study, we have demonstrated that colonization of microbiota from a human preterm infant 
with poor growth resulted in reduced serum levels and liver production of IGF-1. However, microbiota did not 
affect the local brain production of IGF-1 evidenced by the similar Igf1 transcripts in the brain across groups. Our 
data suggest that serum IGF-1, not locally produced IGF-1, may be the main contributor to the different brain 
IGF-1 levels in our three experimental groups. Furthermore, microbiota also affected the brain level of Igfbp3 
mRNA, suggesting that microbiota may influence brain IGF-1 bioavailability.
The effect of microbiota on liver production of IGF-1 may contribute to the decreased IGF-1 circulating levels 
in MPI-L mice since the liver expression levels of Igf1 in MPI-L mice were significantly lower than that of GF mice. 
Modulation of liver production of IGF-1 by microbiota has been shown in several studies; however the extent of 
the influence is inconclusive. Schwarzer et al. report higher liver Igf1 transcripts in SPF mice compared with GF 
mice28. Yan et al. observed higher liver production of IGF1 in GF mice colonized with adult SPF microbiota but 
no transcript difference was detected8. Our study demonstrates that liver production of IGF-1 at early postnatal 
ages can be modulated by early microbial colonization. The associated reduced circulating IGF-1 levels contribute 
to the reduced brain IGF-1 levels in MPI-L mice and correlates with the delayed neuronal development and mye-
lination in the cortex in these pups. Thus, early alteration of microbial colonization may modulate systemic IGF-1 
levels that in turn might impact postnatal brain development.
In conclusion, this study builds on our previous findings demonstrating that early microbiome colonization 
patterns influence growth trajectories, and suggests that colonization of different microbial communities influ-
ences brain development. The initial colonization of microbiota can therefore be a modifiable factor that affects 
brain development. Future studies on specific involvement of certain microbial communities and their metabo-
lites in altering brain development and functions in early postnatal age are warranted and of clinical importance. 
Early optimization of microbial colonization at an early postnatal stage might benefit preterm infants to shape 
brain development and enhance long-term neurological outcomes.
Figure 9. Effects of microbiota on the liver protein and mRNA levels of IGF-1. Liver IGF-1 (A was measured by 
ELISA at four weeks n = 2–5) of age. Relative liver transcripts of Igf1 (B, n = 2–5) at four weeks of age was 
measured by RT-PCR. One-way ANOVA was used to detect the difference among the groups. Bars with  
indicate a significant difference between the two bars (at least p < 0.05).
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Methods
Subjects. This study was designed to investigate the influence of early microbiota on the brain devel-
opment using gnotobiotic mice transplanted with early microbiota from preterm infants. Subjects were 
recruited from the neonatal intensive care unit (NICU) at The Comer Children’s Hospital of the University 
of Chicago. The procedures were approved by the Institutional Review Board (IRB) at University of Chicago 
(protocol #14991B) and written informed consent was obtained from all patient parents. All methods in 
the study on humans were performed in accordance with the guidelines and regulations of the University 
of Chicago.
Animals. All animal procedures were approved by the Institutional Animal Care and Use Committee under 
the animal protocol No. 71703 and performed strictly in accordance with approved Animal Care and Use 
Protocols (ACUPs) at The University of Chicago. Germ free (GF) C57BL/6 J mice were maintained in the gnoto-
biotic facility of the Knapp Center for Biomedical Discovery at the University of Chicago and are routinely tested 
for microbes and parasites by the facility’s staff to ensure germ-free conditions. Colonization experiments were 
carried out as previously described15. Briefly, eight to nine week old pregnant GF mice were transfaunated with 
fecal samples of the preterm human infant donors on E15. Pups were born naturally and nursed by respective 
mothers until weaning. Early (<two weeks of life) preterm human infant microbiota as representative of the first 
microbiota to encounter the host were used in the transfaunation since our previous study showed distinct clus-
tering of microbial samples prior to two weeks of life16. Corresponding to the growth phenotype, pups from GF 
dams transfaunated with fecal samples from an infant with poor growth were identified in this study as MPRETERM 
INFANT-Low (MPI-L), and pups from GF dams transfaunated with fecal samples from an infant with good growth 
were identified as MPRETERM INFANT-High (MPI-H).
Western blotting. Brain tissues were homogenized in ice-cold 1× RIPA lysis buffer (50 mM Tris-Cl at 
pH = 7.5, 150 mM NaCl, 1% NP-40 alternative (EMD Millipore Corporation, La Jolla, CA), 0.5% (wt/vol) Sodium 
deoxycholate, 0.1% (wt/vol) SDS with protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) 
and spun at 12,000 × g for 10 mins. Tissue lysates were then subjected to Pierce® BCA assays (Thermo Scientific 
Inc., Waltham, MA) for protein concentration measurement. Equal amount of protein lysate was subjected to 
SDS-PAGE electrophoresis using Bio-Rad Criterion™ XT 4–12% Bis-Tris precast gels (Bio-Rad Laboratories, 
Inc., Hercules, CA) and transferred to PVDF membranes using a semi-dry transfer system (Bio-Rad). The mem-
branes were blocked with 5% nonfat milk (Bio-Rad) in Tris-buffered saline (TBS, 0.02 mol/l Tris–HCl, 0.137 mol/l 
NaCl, pHZ7.5) with 0.1% Tween-20 (TBST) for an hour on a shaker at room temperature. The membranes were 
cut into pieces depending on the molecular weights of the proteins of interest and then incubated with respective 
primary antibodies in 5% NFM in TBST overnight at 4 °C. The membranes were washed four times for 10 min 
each time with TBST and then incubated with secondary antibodies for 1 h at room temperature. The chemilumi-
nescent signal was developed using SuperSignal West Femto maximum sensitivity substrate (Thermo Scientific) 
and captured using a Molecular Imager® ChemiDoc™ XRS + imaging system (Bio-Rad). The density of each 
band was quantified with ImageJ (NIH, Bethesda, MD) and normalized to GAPDH and presented as fold change 
relative to the control.
Immunohistochemistry. Brains were obtained from mice at postnatal age of two weeks (pre-wean) and 
four weeks (post-wean) and embedded in OCT. Eight µm sections were cut with a cryostat and the sections were 
fixed in ice-cold methanol at −20 °C for 20 minutes. After washing with 1 × PBS for three times, the samples 
were permeabilized with PBS with 0.1% triton (PBST) for 15 mins at room temperature. The samples were then 
incubated with blocking solution (5% goat serum) in PBST for one hour at room temperature. Before primary 
antibody application, the tissues were circled using a hydrophobic barrier pen. The tissue sections were incubated 
with respective 50 µl of primary antibody dilution solution overnight at 4 °C. After wash with PBST for three 
times for 15 mins, the sections were then incubated with respective fluorophore-conjugated secondary antibod-
ies for one hour at room temperature. The sections were counterstained with DAPI antifade mounting medium 
(Invitrogen) before coverslips were applied.
RNA Isolation and Real-time PCR. Total RNA from snap frozen brains and livers were isolated using the 
RNeasy® Plus Mini Kit (QIAGEN GmbH, Hilden, Germany). 500 ng of isolated total RNA was used to synthesize 
cDNA using RT2 First Strand Kit from QIAGEN. TaqMan probes and primers (Thermo Scientific) were used for 
gene of interests and the housekeeping gene Gapdh. Gene expression was normalized to the housekeeping gene 
and expressed as fold change of experimental controls.
Antibodies and reagents. Neuronal nuclei (NeuN), Oligodendrocyte transcription factor 2 (Olig2) and 
Neural/glial antigen 2 (NG2) antibodies were purchased from EMD Millipore (Billerica, MA). Myelin basic 
protein (MBP), neurofilament-Light chain (NFL), and GAPDH antibody were purchased from Cell Signaling 
Technology (Danvers, MA). Secondary anti-mouse-HRP and anti-rabbit-HRP antibodies were purchased from 
Santa Cruz Biotechnology, Inc. (Dallas, TX).
ELISA for serum, brain, and liver IGF-1 and IGFBP3. Serum, brain, and liver samples were collected 
and processed for IGF-1and IGFBP3 measurement using Mouse IGF-I or IGFBP3 Quantikine ELISA Kit from 
R&D Systems Inc. (Minneapolis, MN) according to the manufacturer’s instructions, respectively. Equal amount 
of tissue lysates of brain, and liver were applied to ELISA plates after protein concentration measured by Pierce® 
BCA assays (Thermo Scientific). All ELISAs were read with a Multiskan™ GO Microplate Spectrophotometer 
(Thermo Scientific) with PathCorrection protocol.
www.nature.com/scientificreports/
13SCIeNTIfIC RepoRts |  (2018) 8:5443  | DOI:10.1038/s41598-018-23692-w
Brain fatty acid analysis. Brain tissues were collected freshly at two and four weeks of age and snap fro-
zen until analysis. Approximately 50 mg segments of brain were homogenized in 1.0 mL of Phosphate- Buffered 
Saline solution using a Fisher PowerGen 125 homogenizer. Five hundred microliters of the aliquot was removed 
and lipids were extracted using a modified Folch method88,89. Briefly, after the addition of an internal standard 
(30 μg of heptadecanoic acid), the sample was mixed with 3 ml of chloroform: methanol (2:1 v/v) and vortexed. 
The sample was then incubated on ice for 10 min, vortexed and centrifuged at 2500 rpm for 10 min. The bottom 
infranatant was removed and completely dried under nitrogen gas vapors. The dried sample was then methyl-
ated by addition of 0.5 ml 0.0.5 M methanolic NaOH and incubated for 3 min at 100 °C. Once cooled, 0.5 ml of 
BF3-methanol was added, and the sample was incubated at 100 °C for an additional minute. After cooling, the 
sample was mixed with 1 ml of hexane, followed by 6.5 mL saturated NaCl solution. The sample was vortexed and 
centrifuged at 1700 rpm for 4 min and the upper hexane phase was transferred to a fresh vial and quantified by 
gas chromatography-mass spectroscopy (GC-MS). Fatty acids are expressed as a percent of the total fatty acid 
mass (mol %).
Short chain fatty acid (SCFA) analysis. Fecal contents were collected freshly at two and four weeks 
of age, frozen immediately and stored at −80 °C until analysis. Short chain fatty acids were analyzed at 
OmegaQuant (OmegaQuant, LLC, Sioux Falls, SD) by gas chromatography (GC) with flame ionization detec-
tion. Samples were transferred to a screw-cap glass vial which contained heptanoic acid as an internal standard 
(C7:0 FFA) (Nu-Chek Prep). De-Ionized Water and 50% Sulfuric Acid Solution (Fisher Scientific, NJ, USA 
(3.5:1 v/v) was added to each vial. Each sample was homogenized with a homogenizer cleaned between each 
sample. After homogenization anhydrous ethyl ether (Fisher Scientific) was added to each vial and vortexed 
for 1 minute. Samples were then centrifuged at 4 °C for 10 minutes at 3800 rpm. An aliquot of the ethyl ether 
layer was transferred to a GC vial. GC was carried out using a GC2010 Plus Gas Chromatograph equipped with 
an AOC-5000 autosampler with stack cooler (Shimadzu Corporation, Columbia, MD), and a HP-INNOWAX 
30 m column (0.25 mm internal diameter, 0.25 um film thickness; Agilent J&W, USA). The stack cooler was 
kept below 10 °C while samples were kept on an autosampler. Fatty acids were identified by comparison with a 
standard mixture of short chain fatty acids (Sigma, St. Louis, MO) which was also used to determine individual 
fatty acid calibration curves. The 7:0 FFA was used to calculate recovery efficiency of the assay and applied to 
all fatty acids. Fatty acid composition was expressed as a percent of total identified fatty acids and concentra-
tions as µg/mg sample.
Statistical analysis. All data are presented as the mean ± s.e.m. One and two-way ANOVA were used for 
overall comparisons using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). Kruskal-Wallis test was 
used for nonparametric data. Corresponding post-hoc tests were used if there was an overall significance. P < 0.05 
was considered to be significantly different.
Data Availability Statement. The data generated during the current study are available from the corre-
sponding author on reasonable request.
References
 1. Borre, Y. E., Moloney, R. D., Clarke, G., Dinan, T. G. & Cryan, J. F. The impact of microbiota on brain and behavior: mechanisms & 
therapeutic potential. Adv Exp Med Biol 817, 373–403, https://doi.org/10.1007/978-1-4939-0897-4_17 (2014).
 2. Hooper, L. V. Bacterial contributions to mammalian gut development. Trends Microbiol 12, 129–134, https://doi.org/10.1016/j.
tim.2004.01.001 (2004).
 3. Stappenbeck, T. S., Hooper, L. V. & Gordon, J. I. Developmental regulation of intestinal angiogenesis by indigenous microbes via 
Paneth cells. Proc Natl Acad Sci USA 99, 15451–15455, https://doi.org/10.1073/pnas.202604299 (2002).
 4. Grenham, S., Clarke, G., Cryan, J. F. & Dinan, T. G. Brain-gut-microbe communication in health and disease. Front Physiol 2, 94, 
https://doi.org/10.3389/fphys.2011.00094 (2011).
 5. Marsland, B. J., Trompette, A. & Gollwitzer, E. S. The Gut-Lung Axis in Respiratory Disease. Ann Am Thorac Soc 12(Suppl 2), 
S150–156, https://doi.org/10.1513/AnnalsATS.201503-133AW (2015).
 6. Bjorkholm, B. et al. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS One 4, e6958, https://doi.org/10.1371/
journal.pone.0006958 (2009).
 7. Claus, S. P. et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 4, 219, 
https://doi.org/10.1038/msb.2008.56 (2008).
 8. Yan, J. et al. Gut microbiota induce IGF-1 and promote bone formation and growth. Proc Natl Acad Sci USA 113, E7554–E7563, 
https://doi.org/10.1073/pnas.1607235113 (2016).
 9. Diaz Heijtz, R. et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 108, 3047–3052, 
https://doi.org/10.1073/pnas.1010529108 (2011).
 10. Borre, Y. E. et al. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med 20, 509–518, 
https://doi.org/10.1016/j.molmed.2014.05.002 (2014).
 11. Merzenich, M. M., Van Vleet, T. M. & Nahum, M. Brain plasticity-based therapeutics. Front Hum Neurosci 8, 385, https://doi.
org/10.3389/fnhum.2014.00385 (2014).
 12. Larroque, B. et al. Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the 
EPIPAGE study): a longitudinal cohort study. Lancet 371, 813–820, https://doi.org/10.1016/S0140-6736(08)60380-3 (2008).
 13. Woodward, L. J., Edgin, J. O., Thompson, D. & Inder, T. E. Object working memory deficits predicted by early brain injury and 
development in the preterm infant. Brain 128, 2578–2587, https://doi.org/10.1093/brain/awh618 (2005).
 14. Volpe, J. J. Cerebellum of the premature infant: rapidly developing, vulnerable, clinically important. J Child Neurol 24, 1085–1104, 
https://doi.org/10.1177/0883073809338067 (2009).
 15. Lu, L. et al. Transcriptional modulation of intestinal innate defense/inflammation genes by preterm infant microbiota in a 
humanized gnotobiotic mouse model. PLoS One 10, e0124504, https://doi.org/10.1371/journal.pone.0124504 (2015).
 16. Claud, E. C. et al. Bacterial community structure and functional contributions to emergence of health or necrotizing enterocolitis in 
preterm infants. Microbiome 1, 20, https://doi.org/10.1186/2049-2618-1-20 (2013).
 17. Taft, D. H. et al. Intestinal microbiota of preterm infants differ over time and between hospitals. Microbiome 2, 36, https://doi.
org/10.1186/2049-2618-2-36 (2014).
www.nature.com/scientificreports/
1 4SCIeNTIfIC RepoRts |  (2018) 8:5443  | DOI:10.1038/s41598-018-23692-w
 18. Ehrenkranz, R. A. et al. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of 
extremely low birth weight infants. Pediatrics 117, 1253–1261, https://doi.org/10.1542/peds.2005-1368 (2006).
 19. Hellstrom, A. et al. Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development. Acta Paediatr 105, 
576–586, https://doi.org/10.1111/apa.13350 (2016).
 20. Martin, C. R. et al. Nutritional practices and growth velocity in the first month of life in extremely premature infants. Pediatrics 124, 
649–657, https://doi.org/10.1542/peds.2008-3258 (2009).
 21. Yumani, D. F., Lafeber, H. N. & van Weissenbruch, M. M. Dietary proteins and IGF I levels in preterm infants: determinants of 
growth, body composition, and neurodevelopment. Pediatr Res 77, 156–163, https://doi.org/10.1038/pr.2014.172 (2015).
 22. Wehkalampi, K. et al. Reduced body size and shape-related symptoms in young adults born preterm with very low birth weight: 
Helsinki study of very low birth weight adults. J Pediatr 157(421–427), 427 e421, https://doi.org/10.1016/j.jpeds.2010.02.045 (2010).
 23. Baker, J., Liu, J. P., Robertson, E. J. & Efstratiadis, A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75, 
73–82 (1993).
 24. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J. & Efstratiadis, A. Mice carrying null mutations of the genes encoding insulin-like 
growth factor I (Igf-1) and type 1 IGFreceptor (Igf1r). Cell 75, 59–72 (1993).
 25. Walenkamp, M. J. E. et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocr 
Metab 90, 2855–2864, https://doi.org/10.1210/jc.2004-1254 (2005).
 26. Chiesa, C. et al. Ghrelin, leptin, IGF-1, IGFBP-3, and insulin concentrations at birth: is there a relationship with fetal growth and 
neonatal anthropometry? Clin Chem 54, 550–558, https://doi.org/10.1373/clinchem.2007.095299 (2008).
 27. Fernandez, A. M. & Torres-Aleman, I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 13, 225–239, 
https://doi.org/10.1038/nrn3209 (2012).
 28. Schwarzer, M. et al. Lactobacillus plantarum strain maintains growth of infant mice during chronic undernutrition. Science 351, 
854–857, https://doi.org/10.1126/science.aad8588 (2016).
 29. Mottahedin, A. et al. Effect of Neuroinflammation on Synaptic Organization and Function in the Developing Brain: Implications for 
Neurodevelopmental and Neurodegenerative Disorders. Front Cell Neurosci 11, 190, https://doi.org/10.3389/fncel.2017.00190 
(2017).
 30. Cai, Z., Lin, S., Pang, Y. & Rhodes, P. G. Brain injury induced by intracerebral injection of interleukin-1beta and tumor necrosis 
factor-alpha in the neonatal rat. Pediatr Res 56, 377–384, https://doi.org/10.1203/01.PDR.0000134249.92944.14 (2004).
 31. Jin, C., Londono, I., Mallard, C. & Lodygensky, G. A. New means to assess neonatal inflammatory brain injury. J Neuroinflammation 
12, 180, https://doi.org/10.1186/s12974-015-0397-2 (2015).
 32. Leviton, A. et al. Microbiologic and histologic characteristics of the extremely preterm infant’s placenta predict white matter damage 
and later cerebral palsy. the ELGAN study. Pediatr Res 67, 95–101, https://doi.org/10.1203/PDR.0b013e3181bf5fab (2010).
 33. Hansen-Pupp, I. et al. Inflammation at birth is associated with subnormal development in very preterm infants. Pediatr Res 64, 
183–188, https://doi.org/10.1203/PDR.0b013e318176144d (2008).
 34. Andrews, W. W. et al. Early preterm birth: association between in utero exposure to acute inflammation and severe neurodevelopmental 
disability at 6 years of age. Am J Obstet Gynecol 198, 466 e461–466 e411, https://doi.org/10.1016/j.ajog.2007.12.031 (2008).
 35. Crawford, M. A. et al. The potential role for arachidonic and docosahexaenoic acids in protection against some central nervous 
system injuries in preterm infants. Lipids 38, 303–315 (2003).
 36. Chrast, R., Saher, G., Nave, K. A. & Verheijen, M. H. Lipid metabolism in myelinating glial cells: lessons from human inherited 
disorders and mouse models. J Lipid Res 52, 419–434, https://doi.org/10.1194/jlr.R009761 (2011).
 37. Lauritzen, L. et al. DHA Effects in Brain Development and Function. Nutrients 8, https://doi.org/10.3390/nu8010006 (2016).
 38. Carver, J. D., Benford, V. J., Han, B. & Cantor, A. B. The relationship between age and the fatty acid composition of cerebral cortex 
and erythrocytes in human subjects. Brain Res Bull 56, 79–85 (2001).
 39. Tam, E. W. et al. Early postnatal docosahexaenoic acid levels and improved preterm brain development. Pediatr Res 79, 723–730, 
https://doi.org/10.1038/pr.2016.11 (2016).
 40. Carlson, S. E., Ford, A. J., Werkman, S. H., Peeples, J. M. & Koo, W. W. Visual acuity and fatty acid status of term infants fed human 
milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr Res 39, 882–888, https://
doi.org/10.1203/00006450-199605000-00024 (1996).
 41. Carlson, S. E. & Werkman, S. H. A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until two 
months. Lipids 31, 85–90 (1996).
 42. Martin, C. R. Fatty acid requirements in preterm infants and their role in health and disease. Clin Perinatol 41, 363–382, https://doi.
org/10.1016/j.clp.2014.02.007 (2014).
 43. Friedrich, M. J. Unraveling the influence of gut microbes on the mind. JAMA 313, 1699–1701, https://doi.org/10.1001/
jama.2015.2159 (2015).
 44. Bourassa, M. W., Alim, I., Bultman, S. J. & Ratan, R. R. Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet 
improve brain health? Neurosci Lett 625, 56–63, https://doi.org/10.1016/j.neulet.2016.02.009 (2016).
 45. Braniste, V. et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med 6, 263ra158, https://doi.
org/10.1126/scitranslmed.3009759 (2014).
 46. Fung, T. C., Olson, C. A. & Hsiao, E. Y. Interactions between the microbiota, immune and nervous systems in health and disease. Nat 
Neurosci 20, 145–155, https://doi.org/10.1038/nn.4476 (2017).
 47. Mayer, E. A. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 12, 453–466, https://doi.org/10.1038/
nrn3071 (2011).
 48. Mayer, E. A., Knight, R., Mazmanian, S. K., Cryan, J. F. & Tillisch, K. Gut microbes and the brain: paradigm shift in neuroscience. J 
Neurosci 34, 15490–15496, https://doi.org/10.1523/JNEUROSCI.3299-14.2014 (2014).
 49. Mullen, R. J., Buck, C. R. & Smith, A. M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 116, 201–211 (1992).
 50. Szaro, B. G. & Strong, M. J. Post-transcriptional control of neurofilaments: New roles in development, regeneration and 
neurodegenerative disease. Trends Neurosci 33, 27–37, https://doi.org/10.1016/j.tins.2009.10.002 (2010).
 51. Sakry, D. & Trotter, J. The role of the NG2 proteoglycan in OPC and CNS network function. Brain Res 1638, 161–166, https://doi.
org/10.1016/j.brainres.2015.06.003 (2016).
 52. Zuchero, J. B. & Barres, B. A. Intrinsic and extrinsic control of oligodendrocyte development. Curr Opin Neurobiol 23, 914–920, 
https://doi.org/10.1016/j.conb.2013.06.005 (2013).
 53. Zuchero, J. B. et al. CNS myelin wrapping is driven by actin disassembly. Dev Cell 34, 152–167, https://doi.org/10.1016/j.
devcel.2015.06.011 (2015).
 54. Iacobucci, G. J. & Popescu, G. K. NMDA receptors: linking physiological output to biophysical operation. Nat Rev Neurosci 18, 
236–249, https://doi.org/10.1038/nrn.2017.24 (2017).
 55. Liu, X. B., Murray, K. D. & Jones, E. G. Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during 
early postnatal development. J Neurosci 24, 8885–8895, https://doi.org/10.1523/JNEUROSCI.2476-04.2004 (2004).
 56. Liu, L. et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304, 1021–1024, 
https://doi.org/10.1126/science.1096615 (2004).
 57. Zurek, A. A. et al. Sustained increase in alpha5GABAA receptor function impairs memory after anesthesia. J Clin Invest 124, 
5437–5441, https://doi.org/10.1172/JCI76669 (2014).
www.nature.com/scientificreports/
1 5SCIeNTIfIC RepoRts |  (2018) 8:5443  | DOI:10.1038/s41598-018-23692-w
 58. Tan, S., Rudd, J. A. & Yew, D. T. Gene expression changes in GABA(A) receptors and cognition following chronic ketamine 
administration in mice. PLoS One 6, e21328, https://doi.org/10.1371/journal.pone.0021328 (2011).
 59. Sudo, N. et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J 
Physiol 558, 263–275, https://doi.org/10.1113/jphysiol.2004.063388 (2004).
 60. Tognini, P. Gut Microbiota: A Potential Regulator of Neurodevelopment. Front Cell Neurosci 11, 25, https://doi.org/10.3389/
fncel.2017.00025 (2017).
 61. Basu, A., Krady, J. K. & Levison, S. W. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 78, 151–156, https://
doi.org/10.1002/jnr.20266 (2004).
 62. Rothwell, N. J. & Luheshi, G. N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 23, 618–625 
(2000).
 63. Leitner, K. et al. IL-1 receptor blockade prevents fetal cortical brain injury but not preterm birth in a mouse model of inflammation-
induced preterm birth and perinatal brain injury. Am J Reprod Immunol 71, 418–426, https://doi.org/10.1111/aji.12216 (2014).
 64. Fricks-Gleason, A. N. & Keefe, K. A. Evaluating the role of neuronal nitric oxide synthase-containing striatal interneurons in 
methamphetamine-induced dopamine neurotoxicity. Neurotox Res 24, 288–297, https://doi.org/10.1007/s12640-013-9391-6 (2013).
 65. Topping, D. L. Short-chain fatty acids produced by intestinal bacteria. Asia Pac J Clin Nutr 5, 15–19 (1996).
 66. Juul, A. et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and 
adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol 
Metab 80, 2534–2542, https://doi.org/10.1210/jcem.80.8.7543116 (1995).
 67. Phillips, L. S., Pao, C. I. & Villafuerte, B. C. Molecular regulation of insulin-like growth factor-I and its principal binding protein, 
IGFBP-3. Prog Nucleic Acid Res Mol Biol 60, 195–265 (1998).
 68. Belfort, M. B. et al. Infant growth before and after term: effects on neurodevelopment in preterm infants. Pediatrics 128, e899–906, 
https://doi.org/10.1542/peds.2011-0282 (2011).
 69. Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. 
Cell 155, 1451–1463, https://doi.org/10.1016/j.cell.2013.11.024 (2013).
 70. De Palma, G. et al. Microbiota and host determinants of behavioural phenotype in maternally separated mice. Nat Commun 6, 7735, 
https://doi.org/10.1038/ncomms8735 (2015).
 71. Desbonnet, L. et al. Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour. Brain Behav 
Immun 48, 165–173, https://doi.org/10.1016/j.bbi.2015.04.004 (2015).
 72. Neufeld, K. A., Kang, N., Bienenstock, J. & Foster, J. A. Effects of intestinal microbiota on anxiety-like behavior. Commun Integr Biol 
4, 492–494, https://doi.org/10.4161/cib.4.4.15702 (2011).
 73. Carlson, A. L. et al. Infant Gut Microbiome Associated With Cognitive Development. Biol Psychiatry, https://doi.org/10.1016/j.
biopsych.2017.06.021 (2017).
 74. Lyall, A. E. et al. Dynamic Development of Regional Cortical Thickness and Surface Area in Early Childhood. Cereb Cortex 25, 
2204–2212, https://doi.org/10.1093/cercor/bhu027 (2015).
 75. Paus, T. et al. Structural maturation of neural pathways in children and adolescents: in vivo study. Science 283, 1908–1911 (1999).
 76. Deoni, S. C. et al. Mapping infant brain myelination with magnetic resonance imaging. J Neurosci 31, 784–791, https://doi.
org/10.1523/JNEUROSCI.2106-10.2011 (2011).
 77. Dumas, T. C. Developmental regulation of cognitive abilities: modified composition of a molecular switch turns on associative 
learning. Prog Neurobiol 76, 189–211, https://doi.org/10.1016/j.pneurobio.2005.08.002 (2005).
 78. van der Burg, J. W. et al. The role of systemic inflammation linking maternal BMI to neurodevelopment in children. Pediatr Res 79, 
3–12, https://doi.org/10.1038/pr.2015.179 (2016).
 79. Martin, C. R. et al. Neurodevelopment of extremely preterm infants who had necrotizing enterocolitis with or without late 
bacteremia. J Pediatr 157, 751–756 e751, https://doi.org/10.1016/j.jpeds.2010.05.042 (2010).
 80. Leviton, A. Preterm birth and cerebral palsy: is tumor necrosis factor the missing link? Dev Med Child Neurol 35, 553–558 (1993).
 81. Banks, W. A., Ortiz, L., Plotkin, S. R. & Kastin, A. J. Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are 
transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther 259, 988–996 (1991).
 82. Tao-Cheng, J. H., Nagy, Z. & Brightman, M. W. Tight junctions of brain endothelium in vitro are enhanced by astroglia. J Neurosci 
7, 3293–3299 (1987).
 83. Chakravarty, S. & Herkenham, M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during 
endotoxemia, independent of systemic cytokines. J Neurosci 25, 1788–1796, https://doi.org/10.1523/JNEUROSCI.4268-04.2005 
(2005).
 84. Barichello, T. et al. A kinetic study of the cytokine/chemokines levels and disruption of blood-brain barrier in infant rats after 
pneumococcal meningitis. J Neuroimmunol 233, 12–17, https://doi.org/10.1016/j.jneuroim.2010.10.035 (2011).
 85. Dyer, A. H., Vahdatpour, C., Sanfeliu, A. & Tropea, D. The role of Insulin-Like Growth Factor 1 (IGF-1) in brain development, 
maturation and neuroplasticity. Neuroscience 325, 89–99, https://doi.org/10.1016/j.neuroscience.2016.03.056 (2016).
 86. Beck, K. D., Powell-Braxton, L., Widmer, H. R., Valverde, J. & Hefti, F. Igf1 gene disruption results in reduced brain size, CNS 
hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 14, 717–730 (1995).
 87. Popken, G. J. et al. In vivo effects of insulin-like growth factor-I (IGF-I) on prenatal and early postnatal development of the central 
nervous system. Eur J Neurosci 19, 2056–2068, https://doi.org/10.1111/j.0953-816X.2004.03320.x (2004).
 88. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. J 
Biol Chem 226, 497–509 (1957).
 89. Martin, C. R. et al. Use of a novel docosahexaenoic acid formulation vs control in a neonatal porcine model of short bowel syndrome 
leads to greater intestinal absorption and higher systemic levels of DHA. Nutr Res 39, 51–60, https://doi.org/10.1016/j.
nutres.2017.02.004 (2017).
Acknowledgements
This work was supported by NIH grants R01 HD083481 to E. Claud and R01 DK104346 to C. Martin.
Author Contributions
J.L. performed biochemical assays, WB, immunohistochemical staining, RT-PCR and data analysis; L.L. and 
Y.Y.Y. contributed to the animal experiments and sample collection; J.C.B. performed the brain fatty acid analysis; 
J.L. and E.C. designed the study. J.L., C.M., and E.C. wrote the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-23692-w.
Competing Interests: The authors declare no competing interests.
www.nature.com/scientificreports/
1 6SCIeNTIfIC RepoRts |  (2018) 8:5443  | DOI:10.1038/s41598-018-23692-w
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
